Videos

REVIEW UroToday

Logout

Prostate Cancer

Search

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi Details Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...
Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi Details Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...
The Biology of Prostate Cancer - Kenneth Pienta Details Kenneth Pienta joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019) to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer. The STAMPEDE data sho...
The Use of Novel Imaging Methods in Prostate Cancer - Stefano Fanti Details Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...
The IRONMAN - An International Registry for Men with Advanced Prostate Cancer - Dana Rathkopf Details At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) Dana Rathkopf and Alicia Morgans discuss the IRONMAN registry. Dana, a strong contributor to the IRONMAN registry trial, explains the goals of the registry and why it is so important for the personalization of patient care around the world. The IRONMAN registry is a population-based observational study currently in nine co...
The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain Details Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...
The "Cons" of Treating nmCRPC - Important Considerations to Take into Account Presentation - Celestia Higano Details Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...

Powered by UroToday

This private journal is supported by Astellas Farma Columbia